This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dennehy, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dennehy, P. H.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2008, p. 198-208, Vol. 21, No. 1
0893-8512/08/$08.00+0     doi:10.1128/CMR.00029-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Rotavirus Vaccines: an Overview

Penelope H. Dennehy*

Division of Pediatric Infectious Diseases, Hasbro Children's Hospital, Department of Pediatrics, The Warren Alpert Medical School of Brown University, Providence, Rhode Island

Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children worldwide and continues to have a major global impact on childhood morbidity and mortality. Vaccination is the only control measure likely to have a significant impact on the incidence of severe dehydrating rotavirus disease. In 1999, a highly efficacious rotavirus vaccine licensed in the United States, RotaShield, was withdrawn from the market after 14 months because of its association with intussusception. Two new live, oral, attenuated rotavirus vaccines were licensed in 2006: the pentavalent bovine-human reassortant vaccine (RotaTeq) and the monovalent human rotavirus vaccine (Rotarix). Both vaccines have demonstrated very good safety and efficacy profiles in large clinical trials in western industrialized countries and in Latin America. Careful surveillance has not revealed any increased risk of intussusception in the vaccinated groups with either vaccine. The new rotavirus vaccines are now introduced for routine use in a number of industrialized and developing countries. These new safe and effective rotavirus vaccines offer the best hope of reducing the toll of acute rotavirus gastroenteritis in both developed and developing countries.

* Mailing address: Division of Pediatric Infectious Diseases, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903. Phone: (401) 444-8360. Fax: (401) 444-5650. E-mail: pdennehy{at}lifespan.org

Clinical Microbiology Reviews, January 2008, p. 198-208, Vol. 21, No. 1
0893-8512/08/$08.00+0     doi:10.1128/CMR.00029-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ma, L., El Khoury, A. C., Itzler, R. F. (2009). The Burden of Rotavirus Hospitalizations Among Medicaid and Non-Medicaid Children Younger Than 5 Years Old. AJPH 99: S398-S404 [Abstract] [Full Text]  
  • Rose, J., Hawthorn, R. L, Watts, B., Singer, M. E (2009). Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 339: b3653-b3653 [Abstract] [Full Text]  
  • Desselberger, U., Manktelow, E., Li, W., Cheung, W., Iturriza-Gomara, M., Gray, J. (2009). Rotaviruses and rotavirus vaccines. Br Med Bull 90: 37-51 [Abstract] [Full Text]  
  • Martinez-Laso, J., Roman, A., Rodriguez, M., Cervera, I., Head, J., Rodriguez-Avial, I., Picazo, J. J. (2009). Diversity of the G3 genes of human rotaviruses in isolates from Spain from 2004 to 2006: cross-species transmission and inter-genotype recombination generates alleles. J. Gen. Virol. 90: 935-943 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»